Old Web
English
Sign In
Acemap
>
authorDetail
>
Margit Schmidt
Margit Schmidt
University of Würzburg
Immunology
Blinatumomab
Medicine
Follicular lymphoma
Leukopenia
2
Papers
33
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.
2008
Blood
Max S. Topp
Nikola Goekbuget
Peter Kufer
Gerhard Zugmaier
Evelyn Degenhard
Svenja Neumann
Heinz A Horst
A. Viardot
Mathias Schmid
Oliver G. Ottmann
Margit Schmidt
Carsten Reinhardt
Patrick A Baeuerle
Dirk Nagorsen
Dieter Hoelzer
Ralf Bargou
Show All
Source
Cite
Save
Citations (25)
Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL
2008
Blood
Ralf Bargou
Peter Kufer
Mariele Goebeler
Stefan Knop
Hermann Einsele
Richard Noppeney
A. Viardot
Patrick A Baeuerle
Carsten Reinhardt
Margit Schmidt
Petra Klappers
Dirk Nagorsen
Gerhard Zugmaier
Show All
Source
Cite
Save
Citations (8)
1